Catalog No.
VHJ88801
Species reactivity
Human, Mouse, Rat
Host species
Human
Isotype
IgG4, kappa
Clonality
Monoclonal
Target
ANG-5, Angiopoietin-like protein 3, ANGPT5, Angiopoietin-5, ANGPTL3, Angiopoietin-related protein 3
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9Y5C1
Applications
ELISA, Neutralization
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Iv0160
ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis., PMID:40467521
Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective., PMID:40438928
Evinacumab and reduced lipoprotein apheresis in pediatric homozygous familial hypercholesterolemia: a retrospective study on LDL-C., PMID:40393255
Angiopoietin-like protein inhibitors: Promising agents for the treatment of familial hypercholesterolemia and atherogenic dyslipidemia., PMID:40344904
Genetics of remnant cholesterol., PMID:40277396
Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study., PMID:40167414
Beyond LDL: Targeting ANGPTL3 to Reduce Residual Cardiovascular Risk., PMID:40167412
Treatment With Evinacumab Links a New Pathogenic Variant in the LPL Gene to Persistent Chylomicronemia., PMID:40046103
Evinacumab as an adjunct to lipid apheresis in an infant with homozygous familial hypercholesterolemia., PMID:39970166
Efficacy of a novel PCSK9 inhibitory peptide alone and with evinacumab in a mouse model of atherosclerosis., PMID:39909173
Vaccination as a Promising Approach in Cardiovascular Risk Mitigation: Are We Ready to Embrace a Vaccine Strategy?, PMID:39766344
An up-to-date review of emerging biologic therapies for hypercholesterolemia., PMID:39668448
New drugs for treating dyslipidemias. From small molecules to small interfering RNAs., PMID:39645293
Inhibition of the ANGPTL3/8 Complex for the Prevention and Treatment of Atherosclerotic Cardiovascular Disease., PMID:39565562
Simultaneously blocking ANGPTL3 and IL-1β for the treatment of atherosclerosis through lipid-lowering and anti-inflammation., PMID:39254873
Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and untreated with lipoprotein apheresis., PMID:39054196
Circumventing Cardiovascular Calamities: The Dawn of ANGPTL3 Blockade in Severe Dyslipidemia Management., PMID:39039670
Therapeutic Monoclonal Antibodies for Metabolic Disorders: Major Advancements and Future Perspectives., PMID:39008202
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention., PMID:38970537
APOA5 deficiency causes hypertriglyceridemia by reducing amounts of lipoprotein lipase in capillaries., PMID:38880127
Decreased LDL-Cholesterol Exposure Following ANGPTL3 Inhibition Reduces Coronary Plaque Development in Homozygous Familial Hypercholesterolemia., PMID:38864785
ANGPTL3 as a therapeutic target for treating homozygous familial hypercholesterolaemia: a shot in the arm for evinacumab., PMID:38856677
Evinacumab: Mechanism of action, clinical, and translational science., PMID:38845393
Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia., PMID:38695169
Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies., PMID:38694324
Carboxyl-terminal sequences in APOA5 are important for suppressing ANGPTL3/8 activity., PMID:38625948
Pre-operative levels of angiopoietin protein-like 3 (ANGPTL3) in women diagnosed with high-grade serous carcinoma of the ovary., PMID:38414008
ANGPTL3 Downregulation Increases Intracellular Lipids by Reducing Energy Utilization., PMID:38385290
Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?, PMID:38376536
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups., PMID:38375817
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?, PMID:38372218
Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors., PMID:38299167
Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk., PMID:38243829
A novel fully human anti-NT-ANGPTL3 antibody from phage display library exhibits potent ApoB, TG, and LDL-C lowering activities in hyperlipidemia mice., PMID:38174870
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia., PMID:38095804
Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis., PMID:37689694
Rapid Resolution of Life-Threatening Hypertriglyceridemia after Evinacumab Administration in a Pediatric HSCT Recipient: A Case Report., PMID:37630982
New Biological Therapies for Low-Density Lipoprotein Cholesterol., PMID:37562541
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention., PMID:37486464
Recent advances in the management and implementation of care for familial hypercholesterolaemia., PMID:37460004
Treatment of Homozygous Familial Hypercholesterolemia With ANGPTL3 Inhibitor, Evinacumab., PMID:37305647
Angiopoietin-Like Proteins: Cardiovascular Biology and Therapeutic Targeting for the Prevention of Cardiovascular Diseases., PMID:37295611
Screening of novel serum biomarkers for gastric cancer in coastal populations using a protein microarray., PMID:37290894
A population pharmacokinetic and pharmacokinetic-pharmacodynamic analysis of vupanorsen from phase I and phase II studies., PMID:37170423
Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia., PMID:37071085
Individualized dosing of evinacumab is predicted to yield reductions in drug expenses., PMID:36967323
New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3., PMID:36761060
ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases., PMID:36746257
For research use only. Not for human or drug use.
